Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 11/20 | 0.53 |
| ▸ | FCER2 | P06734 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 13/20 | 0.50 |
| ▸ | MMP3 | P08254 | 7/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP8 | P22894 | 4/20 | 0.49 |
| ▸ | MMP7 | P09237 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19033467 | 1.00 | MEN1 (0.56) | MEN1KMT2ATAAR1EPHX1MMP1 | |
| SCHEMBL10272569 | 0.88 | MMP1 (0.62) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL24833252 | 0.86 | EPHX1 (0.53) | MEN1KMT2ATAAR1EPHX1 | |
| SCHEMBL14495258 | 0.84 | MEN1 (0.53) | MEN1KMT2ATAAR1EPHX1 | |
| SCHEMBL19708164 | 0.84 | MEN1 (0.53) | MEN1KMT2ATAAR1EPHX1 | |
| SCHEMBL13827709 | 0.83 | MEN1 (0.59) | MEN1KMT2ATAAR1EPHX1MMP2 | |
| SCHEMBL19042806 | 0.83 | MEN1 (0.59) | MEN1KMT2ATAAR1EPHX1MMP2 | |
| SCHEMBL20863045 | 0.83 | TAAR1 (0.64) | MEN1KMT2ATAAR1EPHX1MMP9 | |
| SCHEMBL697901 | 0.83 | EPHX1 (0.61) | MEN1KMT2ATAAR1EPHX1MMP2 | |
| Benzene SCHEMBL27636787 | 0.83 | EPHX1 (0.61) | MEN1KMT2ATAAR1EPHX1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020216240-A1 | DICYCLIC ALKANE COMPOUND USEFUL AS INHIBITOR OF PLASMA KALLIKREIN | 南京明德新药研发有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | MEN1 1012/4885KMT2A 1668/4885TAAR1 4654/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MEN1 1631/4885KMT2A 4176/4885TAAR1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.